Alan Liddle is the Non-Executive Chairman and Co-Founder of the Company and has been a Director since the Company's incorporation.
Dr. Chris Baldwin is the Chief Executive Officer and Managing Director of HaemaLogiX.
Dr Geoff Nichol is an Executive Director and Chief Operating Officer at Haemalogix, and was appointed a Director in June 2022.
Dr Rosanne Dunn is an Executive Director and the Chief Scientific Officer at HaemaLogiX, and was a Co-Founder of the Company and has been a Director since the Company's incorporation.
Bryce Carmine is a Non-Executive Director at HaemaLogiX and was a Co-Founder of the Company and has been a Director since the Company's incorporation.
Dr Laurence Turka is a Non-Executive Director at HaemaLogiX and was appointed a Director in February 2024.
Dr Chris Baldwin is Chief Executive Officer and Managing Director of HaemaLogiX, appointed in January 2026. He has more than two decades of experience across biotechnology and precision therapeutics in Australia, the Asia-Pacific, Europe and the United States, including C-suite and founder roles at ASX-listed and international companies.
Dr John Cullity is the Non-Executive Chairman of HaemaLogiX and a co-founder. He is Managing Director at BioSynergy Partners, a New Jersey life-sciences advisory firm, and has held senior roles at Sanofi and Schering-Plough and served as Chair of Race Oncology (ASX: RAC).
Dr Rosanne Dunn is Chief Scientific Officer and an Executive Director of HaemaLogiX, and a co-founder. She led the discovery of KappaMab™ and the design of the KMCAR™ construct, and heads pre-clinical, translational and clinical development across all programs.
